Compositions and use of EPAS1 inhibitors

Details for Australian Patent Application No. 2009232355 (hide)

Owner Calando Pharmaceuticals, Inc.

Inventors Davis, Mark E.; Heidel, Jeremy D.; Liu, Joanna Yi-Ching

Agent Shelston IP

Pub. Number AU-A-2009232355

PCT Pub. Number WO2009/123764

Priority 61/123,069 04.04.08 US

Filing date 3 April 2009

Wipo publication date 8 October 2009

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

28 October 2010 PCT application entered the National Phase

  PCT publication WO2009/123764 Priority application(s): WO2009/123764

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009232365-Soft frozen liquid egg product

2009232353-Method of screening single cells for the production of biologically active agents